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Abstract: Prostate specific membrane antigen (PSMA) has become a major focus point in the research
and development of prostate cancer (PCa) imaging and therapeutic strategies using radiolabeled
tracers. PSMA has shown to be an excellent target for PCa theranostics because of its high expression
on the membrane of PCa cells and the increase in expression during disease progression. Therefore,
numerous PSMA-targeting tracers have been developed and (pre)clinically studied with promising
results. However, many of these PSMA-targeting tracers show uptake in healthy organs such as
the salivary glands, causing radiotoxicity. Furthermore, not all patients respond to PSMA-targeted
radionuclide therapy (TRT). This created the necessity of additional preclinical research studies in
which existing tracers are reevaluated and new tracers are developed in order to improve PSMA-TRT by
protecting the (PSMA-expressing) healthy organs and improving tumor uptake. In this review we will
give an overview of the recent preclinical research projects regarding PCa-TRT using PSMA-specific
radiotracers, which will give an indication of where the PSMA-TRT research movement is going and
what we can expect in future clinical trials.
Keywords: prostate specific membrane antigen; prostate cancer; targeted radionuclide therapy
1. Introduction
Prostate cancer (PCa) is a major public health problem; approximately 450,000 men have been
diagnosed with PCa in Europe in 2018 [1]. Although the 5 year survival rate for local and regional PCa
is 99%–100%, this rate drops to 30% for patients with metastasized PCa [2]. Currently, prostate-specific
antigen (PSA) level measurements, digital rectal examination, and Gleason score grading are being
used for the diagnosis and staging of PCa. Current treatment options for PCa patients involve
surgery and radionuclide therapy for local disease, while hormone therapy, anti-androgen therapy,
and chemotherapy are therapeutic options for advanced disease [3]. Patients at high risk for metastatic
disease, based on high plasma PSA, but with negative prostate biopsy or patients with rising PSA levels
after local treatment with curative intent, undergo additional staging using computed tomography (CT),
whole body magnetic resonance imaging (MRI), or 18F choline-based positron emission tomography
(PET)/CT. These imaging techniques unfortunately have limited sensitivity for detecting small metastatic
lesions [4].
In 1987, the type II transmembrane enzymatic protein prostate specific membrane antigen (PSMA)
was discovered as a novel antigenic marker in PCa cells and serum of PCa patients [5]. PSMA is
overexpressed in 90%–100% of PCa cases and the level of PSMA expression is highly correlated
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with disease progression, with high PSMA expression being found in hormone-resistant tumors and
metastases [6–8]. The overexpression of PSMA on (metastasized) PCa cells makes it an excellent target
for imaging and therapy using PSMA-targeting tracers. These tracers can be labeled with different
varieties of radionuclides for diagnostic (e.g., positron emitter gallium-68) or therapeutic purposes
(e.g., beta-particle emitter lutetium-177 or alpha-particle emitter actinium-225). The radiolabeled tracers
are administered intravenously and will accumulate at the tumor sites due to their PSMA-targeting
properties. Radioactive decay of the alpha and beta particle emitting radionuclides can induce
DNA damage which ultimately may lead to cancer cell death. The excellent potential application of
PSMA-targeting tracers resulted in the development of a multitude of different tracers for diagnostic
and therapeutic purposes.
The high interest in PSMA-targeted radionuclide therapy (TRT) led to a quick movement from
preclinical research to clinical trials, which are showing very promising results. However, next to PCa
cells, expression of PSMA is also found in healthy prostate tissue, the small intestine, central nervous
system, proximal renal tubules, and the salivary and lacrimal glands [9–11]. These PSMA-expressing
organs show uptake of almost all PSMA-targeting radiotracers, which might cause toxicity. Especially
when using an alpha particle-emitting radionuclide (e.g., actinium-225), severe xerostomia can occur,
which can have an enormous negative impact on the quality of life of the patients [12].
The high number of developed PSMA-specific tracers and their almost immediate transit to
clinical trials offered a major advantage in the treatment of metastasized PCa patients. However,
as described above, many tracers showed uptake in healthy organs causing radiotoxicity and not all
patients responded to PSMA-TRT [13]. This created the necessity of additional preclinical research
studies in which existing tracers were reevaluated and improved tracers were developed.
In this review we will give an overview of the recent preclinical research projects regarding PCa
TRT using PSMA-specific radiotracers, with special emphasis on small molecule PSMA inhibitors.
Figure 1 summarizes the preclinical approaches discussed in this review.
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Figure 1. Schematic overview of preclinical research regarding the improvement of prostate specific 
membrane antigen-targeted radionuclide therapy (PSMA-TRT). (A) The basic building blocks of a 
PSMA-targeting small molecule inhibitor consist of a PSMA-binding domain, a linker and a chelator 
which can be labeled with various radionuclides. For each part of the tracer, additions or variations 
are being preclinically studied and described in this review. (B) Next to alterations to the targeting 
molecule, increasing the therapeutic impact on the tumor (left) is tried by combining PSMA-TRT 
with for instance androgen deprivation therapy. Protection of the healthy PSMA-expressing tissue 
(right) is studied by blocking the PSMA-molecule with for instance 2-PMPA. 
1.1. PSMA-Targeting Small Molecule Inhibitors 
Generally, PSMA-targeting small molecule inhibitors consist out of a PSMA binding domain, a 
linker and a domain to which radionuclides can be labeled, such as the chelator 
1,4,7,10-tetra-azacycloododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) or 
1,4,7,10-tetraazacyclododececane,1-(glutaric acid)-4,7,10-triacetic acid (DOTAGA) (Figure 1). 
The development of PSMA-targeting small molecule inhibitors skyrocketed from the moment it 
was discovered that PSMA is chemically identical to NAALADase 
(N-acetyl-alpha-linked-acidic-dipeptidase), a neurotransmitter catalyzer, and to folate hydrolase 1 
(FOLH-1), which is expressed in the jejunal brush border [14]. Already existing inhibitors of 
NAALDase could therefore be used as PSMA-targeting tracers. Furthermore, numerous other small 
molecule inhibitors have been derived and some of those are currently being studied in clinical trials 
(Table 1). An elaborate overview of PSMA-targeting tracer development in the past two decades can 
be found in earlier published reviews [15–21]. 
PSMA-targeting small molecule inhibitors can be divided into three types; urea-based, 
phosphorus-based, and thiol-based. The urea-based compounds have shown superior binding 
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PSMA-Targeting Small Molecule Inhibitors
Generally, PSMA-targeting small molecule inhibitors consist out of a PSMA binding domain,
a linker and a domain to which radionuclides can be labeled, such as the chelator 1,4,7,10-tetra-
azacycloododecane-N,N′,N”,N′′′-tetraacetic acid (DOTA) or 1,4,7,10-tetraazacyclododececane,1-(glutaric
acid)-4,7,10-triacetic acid (DOTAGA) (Figure 1).
The development of PSMA-targeting small molecule inhibitors skyrocketed from the
moment it was discovered that PSMA is chemically identical to NAALADase (N-acetyl-alpha-
linked-acidic-dipeptidase), a neurotransmitter catalyzer, and to folate hydrolase 1 (FOLH-1), which is
expressed in the jejunal brush border [14]. Already existing inhibitors of NAALDase could therefore
be used as PSMA-targeting tracers. Furthermore, numerous other small molecule inhibitors have been
derived and some of those are currently being studied in clinical trials (Table 1). An elaborate overview
of PSMA-targeting tracer development in the past two decades can be found in earlier published
reviews [15–21].
PSMA-targeting small molecule inhibitors can be divided into three types; urea-based,
phosphorus-based, and thiol-based. The urea-based compounds have shown superior binding
Pharmaceutics 2019, 11, 560 4 of 21
affinity for PSMA compared to the other two types. Hence, most (novel) PSMA-specific small molecule
inhibitors carry the urea-based binding domain [22]. These urea-based PSMA binding motifs are
present in three forms: glutamate-urea-lysine (glu-urea-lys), glutamate-urea-glutamate (glu-urea-glu),
or glutamate-urea-cysteine (glu-urea-cys) [23].
Today, PSMA-617 and PSMA-I&T are the tracers most often applied to PSMA-TRT in preclinical
research and clinical trials. Both share the same glu-urea-lys–PSMA binding motif and their
DOTA/DOTAGA chelators enable labeling with therapeutic radionuclides [24,25].
Table 1. Overview of PSMA-targeting small molecule inhibitors suitable for therapy.
Compound Radionuclides PSMA Binding Motif First Reference Clinical Trials
PSMA-617
Lutetium-177
Actinium-225
Indium-111
Gallium-68
Yttrium-90
Urea based
(Glu-urea-lys) [26] [27,28]
PSMA-I&T
Lutetium-177
Actinium-225
Indium-111
Gallium-68
Urea based
(Glu-urea-lys) [29] [30]
MIP-1095 Iodine-123Iodine-131
Urea based
(Glu-urea-lys) [31] [32]
MIP-1072 Iodine-123 Urea based(Glu-urea-lys) [31] [33]
MIP-1404/-1405 Technetium-99m Urea based(Glu-urea-lys) [34] [35]
PSMA I&S Technetium-99m Urea based(Glu-urea-lys) [36] -
CTT1400/CTT1402 Lutetium-177 phosphoramidate-based [37] -
RPS-027 Iodine-131Astatine-211
Urea based
(Glu-urea-lys) [38] -
DCIBzL Iodine-125Iodine-131
Urea based
(Glu-urea-lys) [39] -
2. Improving PSMA-Targeting Small Molecule Inhibitors
Despite the promising results of numerous clinical trials with PSMA-targeting small molecule
inhibitors labeled with beta particle-emitting or alpha particle-emitting radionuclides, a necessity for
optimization of these tracers has become prominent because of the healthy organ toxicity discussed
above [40,41]. Therefore, the majority of preclinical research is focused on developing and/or adjusting
PSMA-targeting tracers to make them safer and better. Different strategies to optimize the tissue
distribution characteristics of the current PSMA-targeting tracers are being applied, for instance by
adding an albumin binding domain or by linker modifications, intending to prevent the uptake in the
salivary glands and kidneys and increase tumor binding.
2.1. Addition of an Albumin Binding Domain
A possible method to reduce toxicity on healthy organs during PSMA-TRT would be to decrease
the injected dose of radiolabeled tracer. However, this might probably lead to a reduction of anti-tumor
efficacy. This problem could be overcome by elongation of the circulation time of the radiolabeled
tracers, most likely leading to an increase in tumor uptake. In this way, a lower quantity of the
radiolabeled tracer can be injected while reaching the same level of tumor targeting [42].
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The circulation time of rapidly cleared molecules can effectively be increased by adding a plasma
protein binding domain [43]. Albumin is an ideal plasma protein target as it is the most abundant
protein in the blood and has a half-life of 19 days in the human blood circulation [44,45]. Next to the
advantage of the increased circulation time, addition of an albumin binding domain is suggested to
have extra advantages. For instance, due to the increased size of the conjugated tracer, the chance
that the radiolabeled compound can accumulate in the tumor increases due to the leaky tumor
vasculature versus the impermeable vascular walls of the healthy tissue [46]. Furthermore, it is
suggested that tumor uptake of albumin conjugated tracers will increase because of the overexpression
in the tumor environment of albumin-binding proteins such as secreted protein acidic and rich in
cysteine SPARC and the glycoprotein 60 (gp60) receptor, which play crucial roles in angiogenesis and
capillary permeability, respectively [47].
The principle of adding an albumin binding domain to increase the circulation time and decrease
normal tissue binding of radiolabeled compounds was first proven by Müller et al., who measured
the binding of [177Lu]Lu-cm09, a folate ligand with an albumin binding domain [48]. This research
showed a 3× higher in vivo tumor uptake 24 h post injection (p.i.) and a 2.5× lower kidney uptake
4 h p.i. of the folate ligand with albumin binding domain compared to [177Lu]Lu -EC0800, the same
folate ligand without albumin binding domain. Subsequently, several research groups conjugated
the 4-(p-iodophenyl)butyric acid as an albumin binding domain to PSMA-targeting small molecule
inhibitors tracers [37,38,49–51]. These PSMA-albumin binding tracers (CTT1403, RPS-027, RPS-063,
DOTA-PSMA-ALB-02 and HTK01169) all successfully showed increased circulation-half-lives and
tumor uptake. However, unlike the findings of Müller et al. with the folate ligands [48], the addition
of this albumin binding domain also dramatically increased the renal uptake for these tracers during
in vivo murine experiments, which may be caused by the increased circulation time. Similar results
were presented by Wang et al. who coupled the truncated Evans blue (tEB) albumin binding domain
to their PSMA-targeting compound (DOTA-EB-MCG) [46].
Follow-up studies aimed to exploit the increased tumor uptake and tried simultaneously to
prevent the increased renal uptake. For this, Umbricht et al. compared the 4-(p-iodophenyl)butyric acid
with a p-(tolyl)-moiety as an albumin binding domain conjugated to the DOTA-PSMA-617 compound,
creating PSMA-ALB-53 and PSMA-ALB-56, respectively [52]. The p-(tolyl)-moiety is a weaker albumin
binder compared to PSMA-ALB-53 and showed a faster in vivo renal clearance when labeled with
lutetium-177. Interestingly, [177Lu]Lu-PSMA-ALB-56 demonstrated a higher tumor uptake compared
to [177Lu]Lu-PSMA-ALB-53 which led to a 3× higher tumor-to-kidney ratio of [177Lu]Lu-PSMA-ALB-56
compared to [177Lu]Lu-PSMA-ALB-53. In vivo therapy studies showed an increased survival benefit
of [177Lu]Lu-PSMA-ALB-56 compared to [177Lu]Lu-PSMA-617, probably due to its higher tumor
uptake. However the tumor-to-kidney ratio of [177Lu]Lu-PSMA-617 was 3× higher compared to
[177Lu]Lu-PSMA-ALB-56. The use of a weaker albumin binder might be an ideal compromise leading
to increased tumor uptake due to the albumin binding, although with enhanced risk for renal toxicity.
Summarized, increased circulation half-life of a PSMA-targeting radiotracer by addition of
an albumin binding domain successfully increased tumor uptake. However, the concomitant significant
increase in renal uptake is unfavorable and should be prevented. Moreover, the longer circulation
time of these adapted tracers might also lead to increased bone marrow toxicity as well as toxicity in
the salivary and lacrimal glands of PCa patients, which has a major negative impact on the quality
of life of these patients. Table 2 gives an overview of the developed albumin binding compounds
described here.
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Table 2. Overview of PSMA-targeting small molecule inhibitors that have been conjugated with an albumin binding domain and their in vivo biodistribution data in
mice. * Values had to be based on graphs rather than exact data as they were not present in the reference.
Compound Radionuclide Albumin Binding Domain In Vivo Model Injected Tumor-to-kidney-Ratio 24 h p.i. Ref.
CTT1402 Lutetium-177 4-(p-iodophenyl) butyric acid NCr nude mice + PC3-PIP tumors 1.85 ± 0.07 MBq4 ± 1 MBq/nmol 0.14 [37]
RPS-027 Iodine-131 4-(4-iodophenyl) butanoic acid NCr-nu/nu mice + LNCaP cell xenografts ∼370 kBq/10 µCi ±2.5 * [38]
DOTA-PSMA-ALB-02 Lutetium-177 4-(p-iodophenyl) butyric acid PC-3 PIP/flu No data 7.16 [50]
HTK01169 Lutetium-177 N-[4-(p-iodophenyl)butanoyl]-Glu LNCaP No data 0.45 [51]
DOTA-EB-MCG Yttrium-90 truncated Evans blue Athymic Nude-Foxn1nu, Envigo + PC3-PIP tumors 3.7–5.1 MBq ±4 * [46]
RPS-072 Lutetium-177 4-(4-iodophenyl) butanoic acid Male BALB/C athymic nu/nu mice + LNCaP tumors 0.36–1.3 MBq13–23 pmol ±4.5 * [53]
RPS-074 Actinium-225 4-(4-iodophenyl) butanoic acid Male BALB/C athymic nu/nu mice + LNCaP tumors 105 kBq 142 pmol 4.3 [54]
PSMA-ALB-53 Lutetium-177 4-(p-iodophenyl)-moiety PC3-PIP tumors 5MBq 100 pmol 2.17 [52]
PSMA-ALB-56 Lutetium-177 p-(tolyl)-moiety PC3-PIP tumors 5MBq 100 pmol 10.8 [52]
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2.2. Linker and Chelator Modifications
Other structural modifications of small molecule inhibitors have been reported in attempts to
improve the therapeutic efficacy and tumor-to-background ratios. One option is to change the linker
molecule in between the PSMA binding domain and chelator, since there is increasing evidence
that PSMA-binding is not only caused by the PSMA-binding motif in these molecules, but also the
hydrophobicity, charge, and overall structure is thought to influence PSMA binding efficacy [55].
Furthermore, it is suggested that binding of PSMA-targeting tracers to, for instance, the salivary glands
might also be due to the hydrophobic character of the linker [56]. Therefore, modification of the linker
can have significant impact on binding affinity, biodistribution, and overall pharmacokinetic properties
of PSMA-targeting small molecule inhibitors [57].
Benesova et al. first showed that modifying the linker between the PSMA-binding domain
and the DOTA chelator can significantly influence the pharmacokinetic properties by optimizing the
linker moiety when creating PSMA-617 small molecule inhibitors [26]. Eighteen chemically different
PSMA-targeting small molecule inhibitors were developed by altering the configuration of the linker.
This resulted in significant changes in the pharmacokinetic properties of the tracers, thereby providing
evidence that linker modification can have an impact on pharmacokinetic properties. The changes
in these linkers did however not lead to superior tumor-targeting and pharmacokinetic properties
compared to PSMA-617. By experimenting with these different linkers, the researchers generated
knowledge of the binding effects of structural changes in PSMA-targeting tracers and proposed that
this may lead to a more rational and structure-aided design and synthesis of novel PSMA-targeting
small molecule inhibitors [55].
Schmidt et al. conjugated a carbohydrate to the linker of PSMA-I&T as a strategy to reduce the
unwanted renal accumulation. They successfully showed the feasibility of the conjugation of such
a bulky carbohydrate moiety to PSMA-I&T. This conjugation had no negative effect on the target
affinity; however, the in vitro internalization rate decreased considerably. Furthermore, no beneficial
effects were shown of the conjugated carbohydrate moiety in vivo [58]. Another linker modification to
a PSMA small molecule inhibitor suitable for therapy was tested by Kuo et al. The authors replaced the
2-naphthylalanine (2-Nal) amino acid of the linker of PMSA-617 with either 2-indanylglycine (Igl) or
3,3-diphenylalanine (Dip), which are close analogs of 2-Nal. Doing so, the researchers hypothesized that
these changes would lead to a stronger interaction with the PSMA target. However, the substitution with
Igl or Dip led to a ~5- and 21-fold decrease, respectively, of in vitro binding affinity. The compound with
the Igl substitution (HTK01166) showed similar in vivo tumor binding as PSMA-617, however an almost
5× higher renal uptake. The Dip replacement (HTK01167) on the other hand, led to a 6× lower kidney
binding and a 2× lower tumor binding. This indicates the potential of HTK01167 as a theranostic tracer
with lower tumor-background ratios and warrants further development [59].
Kelly et al. tried to optimize the binding characteristics of their developed albumin binding
PSMA-tracer RPS-63 via an increased polyethylene glycol (PEG) spacer length between the PSMA
binding domain and the albumin binding domain. The newly synthesized RPS-072 showed a higher
tumor uptake compared to RPS-63 and PSMA-617. The researchers argued that the increased linker
size reduced the retention of the radioligand by increasing its clearance before the tubular reabsorption.
However, besides increased tumor uptake, renal uptake of RPS-072 increased as compared to
PSMA-617 [49].
These examples of linker modifications support the hypothesis that linker structure has an influence
on tracer pharmacokinetic properties and show the feasibility of alternating the structure. However,
none of the previous discussed modifications has led to an increased tumor binding and a decrease in the
binding to the healthy PSMA-expressing organs in comparison to PSMA-617 or PSMA-I&T, respectively.
In addition to altering linker structure, the chelating moiety is also interchangeable and can have
a significant effect on the pharmacokinetics [60,61]. For example, replacing the DOTA chelator of
PSMA-617 with a CHX-A”-DTPA conjugate, Wüstemann et al. showed higher in vitro internalization
rate facilitated by the CHX-A”-DTPA chelator compared to PSMA-617. Furthermore, a progressive
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long-term accumulation in LNCaP tumors in vivo was observed, as the CHX-A”-DTPA conjugate
uptake increased until 3 h p.i. The researchers suggested that this was due to the higher internalization
rate that they measured in vitro. However, it must be noted that the DOTA version of PSMA-617 has
an approximately 2× higher tumor uptake in vivo [57].
Next to changing the chelator moiety of PSMA-targeting tracers, also the addition of an extra
chelator is being investigated as a method to label compounds with both therapeutic and diagnostic
radionuclides. For instance, Wurzer et al. synthesized such a dual-nuclide labeled tracer (gallium-68
for PET and bismuth-213 for therapy) and proved the concept of in vivo monitoring the biodistribution
via PET and therefore enabling precise therapeutic dosimetry. Limitation of this approach is that
radionuclides with matching half-lifes must be used in order to correctly determine dosimetry [62].
In line of this research, Wester et al. proposed the idea for a PSMA radiohybrid (rhPSMA) tracer that
consists of a PSMA binding domain, a radiometal binding chelator and an extra functional group for
covalent fluorine-18 labeling. This rhPSMA tracer will be suitable for PET imaging when labeled with
fluorine-18 and the chelator is filled with a cold/non-radioactive metal, like lutetium-175. When using
this tracer for therapy, the rhPSMA tracer can be labeled with lutetium-177 and fluorine-19. Using this
approach, the tracer used for diagnostic PET imaging and the tracer used for therapy are chemically
100% identical. These rhPSMA tracers therefore will have the same binding affinities, selectivities,
lipophilicities, and pharmacokinetics. This has the advantage of pretherapeutic PET-imaging providing
valid quantitative biodistribution data and dosimetry, which can be used for personal therapeutic
intervention [25].
Thus, the structure of the linker and the type of chelator can have an effect on the overall binding
properties of PSMA-specific agents. Experiments with structural differences in these tracers gives more
insight in PSMA-binding and internalization both in PCa and healthy PMSA-expressing organs and
further research is warranted.
3. Development of Multi- and Bi-Ligands
In order to increase the binding affinity of PSMA-specific tracers, some groups have focused on the
development of homo-multimeric tracers, which contain more than one PSMA-binding domain [62–64].
These multivalent PSMA-specific tracers have shown promising results in vitro, increased binding
affinity, and in vivo, increased tumor retention. However, these tracers have not been introduced in
the clinic for therapeutic purposes yet.
Looking beyond PSMA, PCa cells also express other target proteins that are suitable for TRT.
Combining a PSMA-targeting tracer with a tracer targeting another PCa specific target might increase
uptake in PCa lesions and show enhanced theranostic properties. The probability of a double targeting
tracer, or biligand, to bind to PCa is larger especially of value for tumors with a high heterogeneity
in expression of different targets [65,66]. However, combination of two targeting molecules might
also have the drawback of interfering with binding to the PSMA target or increasing binding on
PSMA-expressing or other healthy organs. Furthermore, increasing the size of PSMA-targeting tracers
may have negative effects on the pharmacokinetic properties.
3.1. Targeting PSMA and Hepsin/Integrins
Various bi-ligands have been developed in which PSMA-targeting tracers are combined with
another specific binding domain. For example, Subedi et al. combined a Lys-urea-Glu moiety
PSMA-binding scaffold with a binding domain targeting hepsin, a membrane serine protease that is
highly upregulated in PCa [67]. Conjugated with the optical dye SulfoCy7, this compound showed
higher binding in PSMA- and hepsin-expressing tumors compared to tracers that target PSMA alone,
which suggests that this PSMA/hepsin heterodimer might be useful in increasing sensitivity of PCa
diagnostic imaging [68]. A PSMA-hepsin heterodimer suitable for radionuclide therapy and the
corresponding healthy organ uptake has not been investigated yet.
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Another example that proves the feasibility of creating PSMA heterodimers is provided by
Shallal et al. Here, the authors combined the PSMA binding domain with a domain targeting αvβ3
integrin reported to be highly upregulated in PCa. The researchers were able to prove in vitro that the
PSMA/αvβ3 integrin heterodimer could bind to both targets; however, the binding affinity was much
lower compared to DCIBzL, a high affinity PSMA binding agent. This compound is being taken further
into preclinical testing by performing quantitative biodistribution assays and imaging in vivo [69].
3.2. Targeting PSMA and the Gastrin-Releasing Peptide Receptor
Another relevant PCa target is the gastrin-releasing peptide receptor (GRPR). GRPR is
a transmembrane G-protein coupled receptor which is overexpressed in 84% of PCa cases, as well as in
other types of cancer, such as breast cancer and small cell lung cancer [70,71]. Beside expression in
tumor tissue, GRPR is expressed in various healthy tissues, such as breast, pancreas, prostate, and
lung [72]. While PSMA expression increases as the disease progresses, GRPR is already overexpressed
in high levels in early PCa stages [71]. Therefore, combined targeting of both PSMA and GRPR could
lead to a high tumor uptake during all disease stages.
In 2014, the first PSMA/GRPR heterodimer ((DUPA-6-Ahx-(64Cu-NODAGA)-5-Ava-BBN(7–14)NH2))
was created by Bandari et al. with the aim to improve PCa imaging [73]. Although this compound did
not show superior imaging properties compared to existing mono-targeting PSMA-tracers, the study did
show that constructing such a PSMA/GRPR targeting tracer was feasible. Rapidly, several PSMA/GRPR
targeting heterodimers were developed and preclinically tested [66,70]. These PSMA/GRPR bi-ligands all
showed specific PSMA and GRPR PCa tumor targeting in vitro and in vivo. However, the combination
of the two targeting domains also combined with undesired high uptake in the kidneys, spleen, and
pancreas. Alterations in the linker compositions by increasing the number of charged amino acids
resulted in a significant decreased uptake in the kidneys and spleen. Unfortunately, it also resulted in
increased uptake of the GRPR-positive pancreas [65].
Because research models of PCa used in the previously described research projects only overexpress
either PSMA or GRPR, but not both targets simultaneously, it is yet impossible to show that combining these
targets will have a synergistic or additive tumor targeting effect. Abouzayed et al. did use an in vivo tumor
model that both expresses PSMA and GRPR, PC3-PIP, while studying their GRPR/PSMA-heterodimer
[125I]I-BO530 [74]. [125I]I-BO530 showed long activity retention in these PC3-PIP tumors however, high
uptake in the kidneys led to unfavorable low tumor-to-kidney ratios of 1.2 ± 0.3 at 24 h p.i. which, so the
researchers argue, could lead to an unacceptably high renal radiation dose. Furthermore, the researchers did
not compare [125I]I-BO530 to a single PSMA-targeting tracer (for instance PSMA-617), which is necessary
in order to prove synergistic advantages of the PSMA-GRPR heterodimer.
These studies showed that it is feasible to create heterodimer tracers that target both PSMA
and GRPR. However, it must be noted that with the addition of the GRPR moiety, the salivary
glands and kidney toxicity caused by PSMA-TRT might be accompanied by the GRPR-TRT toxicity in
GRPR-expressing pancreas. This must be carefully considered before introducing these bi-ligands to
the clinic.
4. Varying Radionuclides for PSMA-TRT
There are different types of radionuclide emissions that can cause cellular/DNA damage and
therefore can be used for therapeutic purposes; Auger/conversion electrons and beta- (β−) and alpha
(α) emission (Figure 2). These emissions have different linear energy transfer (LET, in Kev/um) values
ranging from a few eV for Auger/conversion electrons up to MeV for alpha particles (Table 3). Importantly,
the range of these particles varies. While alpha and beta radiation reaches a range of 40–100 µm and
50–12,000 µm, respectively, Auger/conversion electrons have a very short range of only 0.002–0.5 µm [75].
Delivery of the radiolabeled compounds which carry a radionuclide with such a short range must
therefore be very close to or directly in/near the cell nucleus in order to cause DNA damage.
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Table 3. Overview of adionuclides used in PSMA-TRT (pre)clinical research and their basic characteristics.
Radionuclide Particle Emission T1/2 Eavg KeV (β− or α)
Scandium-47 β− 3.3 days 162
Copper-67 β− 2.6 days 141
Iodine-131 β− 8.0 days 181
Terbium-161 β− 6.9 days 154
Lutetium-177 β− 6.7 days 140
Astatine-211 α 7.2 h 5868
Lead-212 β− 10.6 h 130
Bismuth-213 α 46 min 1390 (max)
Actinium-225 α 9.9 days 5915
Thorium-227 α 18.7 days 6145
4.1. Beta-Emitters
Today, lutetium-177 is most frequently used for PSMA-TRT in the (pre)clinic. With a mean range
of 670 µm and energies of 0.1–2.2 MeV of the beta particles, it is an ideal radionuclide for treatment of
micro-metastases. Lutetium-177 also emits γ-rays during its decay, enabling single photon emission
computed tomography (SPECT) imaging for treatment efficacy predictions. Despite these favorable
properties, clinical studies have shown that approximately 30% of PCa patients did not respond to
lutetium-177 PSMA-TRT [76,77]. Therefore, many (pre)clinical research projects focus on experimenting
with different radionuclides to reach a higher therapeutic efficiency.
Alternative potent beta-emitting radionuclides are copper-67, scandium-47 and terbium-161.
These radionuclides have an energy emission comparable to that of lutetium-177 [78]. Müller et al.
studied the potency of terbium-161 for PSMA-TRT, which, besides beta decay, also emits a considerable
amount of Auger/conversion electrons, leading to a possible increase in total absorbed dose compared to
lutetium-177 [79]. In vivo biodistribution assays revealed comparable biodistribution profiles for
PSMA-617 labeled with lutetium-177 or terbium-161. In vitro, [161Tb]Tb-PSMA-617 had a significantly
higher therapeutic efficiency on PC3-PIP cells compared to [177Lu]Lu-PSMA-617. An in vivo therapy
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study comparing [177Lu]Lu-PSMA-617 and [161Tb]Tb-PSMA-617 is currently lacking, indicating that
additional pre-clinical research is needed to test the potential of these tracers.
4.2. Alpha-Emmiters
Targeted alpha therapy (TAT) has become of high interest for PSMA-TRT. Alpha particles have
much higher LET and a shorter range compared to beta-particles, which can lead to several ionization
events in close proximity to each other within the DNA causing so-called alpha-tracks [80,81]. Therefore,
in comparison to beta decay, alpha decay can cause a high quantity of DNA double strand breaks in
a short range and holds the promise of a higher level of induced DNA damage per cell. Actinium-225,
lead-212, thorium-227, bismuth-213, and astatine-211 are alpha emitting radionuclides that are being
explored (pre)clinically for PSMA-TAT [54,80,82,83]. These studies all prove the increased therapeutic
effectiveness of alpha-radiation compared to beta-radiation. Mice treated with a single dose of
[225Ac]Ac-RPS-074 (148 kBq) even showed total remission underlining the potential of actinium-225
for PSMA-directed radionuclide therapy [54]. The increase in therapeutic efficiency by the use of
alpha-radiation, however, may also lead to an increase in (late) onset of toxicity. Preclinical in vivo
studies did not address these long-term toxicity effects, however, several clinical PSMA-TRT studies
with actinium-225 reported irreversible damage to lacrimal and salivary glands, causing xerostomia [84].
Xerostomia is one of the major concerns for PSMA targeting therapy as it has a major negative impact
on the quality of life of the patients and should therefore be prevented.
Lead-212 emits beta-particles and decays into bismuth-212, which emits alpha-particles. Lead-212
is suggested as a potent alternative for actinium-225 because of its shorter half-life (10 h vs. 10 days)
and fewer alpha emitting daughters (1 vs. 3), thus potentially lower normal organ toxicity risks [85,86].
Banerjee et al. recently published their proof-of-concept of a novel [212Pb]Pb-labeled L2, a PSMA
low molecular weight compound [86]. In vivo murine dose-dependent tumor growth inhibition
was demonstrated, resulting in increased survival benefit when compared to [177Lu]Lu-PSMA-617.
Unfortunately, long term renal toxicity was observed in healthy non-tumor bearing mice after a single
administration of [212Pb]Pb-L2, revealing the kidneys as dose-limiting organs in mice.
Taken together, various radionuclides with different characteristics have been tested in preclinical
experiments for their efficacy and toxicity for PSMA-TRT. Currently, lutetium-177 is most frequently
used in the (pre)clinic, followed by actinium-225. Further preclinical and clinical research is required
to define the most optimal tracer-radionuclide combination which combines the highest therapeutic
efficiency with the lowest toxicity. Further description of current PSMA-TAT research can be found in
the review of Chakravarty et al. [40].
5. Enhancement of Therapy Effect
So far, we have elaborately discussed the approaches used to develop novel or adjust existing
tracers in order to increase the therapeutic efficacy of PSMA-TRT. The variations in tracer structures
and combinations are in theory endless and thus might result in the development of a magnitude of
different PSMA-targeting tracers. Another strategy in order to reach a higher therapeutic efficacy may
be combining PSMA-TRT with other (existing) therapies for PCa [87,88]. For example, using other
agents to increase the PSMA expression on tumor cells or to increase the radiosensitivity of the tumor
could significantly increase PSMA-TRT outcome.
Chemical radiosensitizers are compounds that are intended to increase the level of damage
induced by ionizing radiation [89]. This combination strategy has been widely researched and clinically
adapted for PCa external beam radiation therapy (EBRT) and has shown promising increases in
therapeutic efficacy [90]. Radiosensitizing agents can be divided into three working mechanism
categories; agents that dysregulate the cell cycle, agents that inhibit DNA damage repair, and agents
that cause oxygenated stress.
Radiosensitization in combination with PSMA-TRT has not yet thoroughly been investigated.
Tesson et al. combined and compared the therapeutic effect of PSMA-TRT with several radiosensitizing
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compounds in a preclinical setting [91]. When combining [131I]I-MIP-1095 with either an oxidizing
agent (disulfiram), p53 pathway inhibitor (nutlin-3), proteasome inhibitor (bortezomib), or a PARP-1
inhibitor (olaparib), the researchers found an increased growth inhibition on LNCaP spheroids in vitro.
Other possible radiosensitizers to combine with PSMA-TRT are androgen deprivation therapy
(ADT) or anti-androgens, such as enzalutamide and apalutamide. These treatments are already being
used for the treatment of locally advanced PCa and non-metastatic castration-resistant PCa [92–94].
Various clinical studies have reported an overall survival benefit of ADT when combined with
EBRT [95–97]. Recent preclinical work has revealed that enzalutamide and apalutamide act as
radiosensitizers of EBRT via downregulation of the DNA double strand break repair capacity of PCa
cells [98–100]. PSMA expression is thought to be regulated by androgens although reports showed
conflicting results. While several studies have reported an increase in the level of PSMA expression in
PCa cell-lines and in tumor tissue of patients after ADT [101–103], others describe a downregulation of
PSMA expression caused by ADT [104,105]. Preclinical in vivo studies have so far been unsuccessful
in showing an additive therapeutic effect on the tumor growth of this combination therapy [106].
Clearly, the added value of ADT in combination with PSMA-TRT and its mechanism of action is
unresolved [107].
Alternative combination options, for instance EBRT, immunotherapy or other radiosensitizers that
are proposed for increasing PSMA-TRT efficacy need to be further explored. Clearly, more preclinical
research is warranted to establish potential synergistic or additive effects of combination therapy
with PSMA-TRT.
6. Protection of PSMA Expressing Kidneys and Salivary Glands
One of the major disadvantages of PSMA-TRT is the high accumulation of the radiolabeled tracers
in healthy PSMA-expressing organs, the kidneys and salivary glands. Despite the high uptake in the
kidneys, there is very little reported on renal toxicity after PSMA-TRT. This could be explained by
the fact that most patients receive PSMA-TRT as a last-option therapy and therefore follow-up is not
long enough to detect (late) onset of renal toxicity [108]. However, when PSMA-TRT will be used for
patients that are in an early stage of (high risk) PCa with (oligo)-metastatic disease, renal toxicity might
become of major concern [109].
PSMA-TAT with actinium-225 has been reported to cause severe and irreversible salivary gland
toxicity leading to xerostomia [110]. Xerostomia can have a major impact on the quality of life of
the PCa patients that receive the potentially life-elongating PSMA-TRT: in a recent study, 10% of the
patients chose to discontinue their treatment for this reason [84]. Clinical studies have investigated
various strategies in order to find a method to protect the salivary glands. Amongst others, external
cooling of the salivary glands with ice-packs, saline irrigation, steroid injection, botulinum toxin
injections, and oral administration of folic polyglutamate tablets have been evaluated, but with no
significant decrease in salivary gland uptake of PSMA-targeting tracers or in too few patients to enable
statistical analysis [25,108,111,112].
There clearly is an urgent need to conduct preclinical research to test strategies to protect the
salivary glands from damage during PSMA-TRT. However, the lack of a proper in vivo research model
for salivary gland PSMA-TRT damage is a major drawback and relatively few preclinical studies have
been published on this topic. Mice have high levels of PSMA expression in the brain, kidneys, and
salivary glands, at similar levels to that observed in humans. However, in contrast to humans, mice
have very low to no PSMA expression in the prostate and jejunum. Furthermore, despite the high
PSMA expression in murine salivary glands, biodistribution assays with various PSMA-targeting
tracers did not show any, or very low salivary gland uptake, while renal uptake is similar or even higher
in mice compared to humans [113–116]. This difference in PSMA expression might be explained by the
difference in PSMA amino acid sequence between humans and mice (91% similarity). Furthermore,
the PSMA structures in murine kidneys and salivary glands have been reported to differ [117,118].
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Finally, the high PSMA binding in the salivary gland in humans may not only be due to PSMA
expression, but might also be the result of non-specific binding [119,120].
Roy et al. aimed to identify an animal model that resembles human salivary gland uptake of
PSMA-TRT and compared the salivary glands uptake of [18F]F-DcFPYL in NCR-nu/nu athymic female
mice and F344/SAS Fischer female rats [121]. Biodistribution assays revealed a 2- to 3-fold higher
uptake of [18F]F-DcFPYL in mice submandibular and sublingual glands compared to that of rats.
Additional in vitro autoradiography studies on human, mouse, and rat salivary glands showed similar
binding of [18F]F-DcFPYL for the mouse and human salivary glands. Therefore, they argued that
this mouse model is a more suitable research model for PSMA-TRT compared to the rat. However,
since the relative uptake of the PSMA-targeted tracer in the murine salivary glands in this study was
not comparable to the high uptake in the human salivary glands, it is still questionable whether the
NCR-nu/nu mice represent an appropriate research model to examine PSMA-TRT toxicity effects.
Despite the lack of preclinical models that adequately resemble human salivary gland uptake of
PSMA-targeting tracers, a few studies reported on protective strategies for the salivary glands and/or
kidneys. Rousseau et al. used LNCap-tumor bearing NOD SCID gamma (NSG) mice to demonstrate
that administration of monosodium glutamate (MSG), a well-known food additive, can reduce uptake
of [68Ga]Ga-PSMA-11 in the salivary glands and kidneys without affecting uptake in the tumor. Because
the majority of PSMA ligands integrate glutamate to bind to PSMA, the administration of MSG may
act by blocking this process and thereby decreasing non-specific binding in healthy organs [122].
Another strategy that was tested, was the use of 2-(phosphonomethyl)pentane-1,5-dioic acid
(2-PMPA), a well-known PSMA inhibitor which is frequently used as a competitor for PSMA-targeted
tracers [123]. It was shown that administration of 2-PMPA decreased binding of PSMA-targeted tracers
in the kidneys in a dose dependent manner, but at the expense of (to a lesser extent) decreased uptake
in the tumor [31,113,116]. In line of this research it has been reported that slightly decreasing the
molar activity, or the using low concentrations of unlabeled or non-radioactive labeled tracers can
positively influence the tumor-to-kidney-ratio and warrants further research [113,124,125]. In order to
specifically shield the kidneys and salivary glands from PSMA-TRT with 2-PMPA, a novel prodrug
(e.g., Tris-POC-2-PMPA) has been proposed which is suggested to specifically bind in non-malignant
tissues and hence reduce toxicity [126]. Further (pre)clinical research is needed to investigate the
potential of this compound to protect the salivary glands and kidneys without affecting tumor uptake.
Finally, a strategy to reduce renal uptake of PSMA-targeted tracers is the use of mannitol, which
can act as an osmotic diuretic in the PSMA expressing proximal tubules of the kidneys. Because
mannitol promotes diuresis, reabsorption of the PSMA-targeting tracers may decrease, which is
hypothesized to decrease overall renal uptake [127]. However, first clinical imaging studies revealed
that mannitol did not show a significant effect on the uptake of PSMA-specific tracers [108,127].
To summarize, it has become evident that there is an urgent need for PSMA-specific renal and
salivary gland protection for PCa patients receiving PSMA-TRT. The lack of an adequate preclinical
research model to reflect the situation in humans is a major challenge. Increasing evidence suggests that
besides PSMA-specific binding, also non-specific binding of PSMA may play a role in the uptake of
PSMA-targeting tracers in the salivary glands. Further investigations are needed to identify a compound
that is able to selectively block both specific and/or non-specific binding of PSMA tracers in the salivary
glands and the kidneys to improve safety without affecting tumor uptake.
7. Concluding Remarks
PSMA-targeting tracers have made a steep introduction into clinical staging of PCa and a fast
implementation towards PSMA-TRT. This fast clinical integration, however, requires preclinical research
to assure optimal use with maximal safety. Preclinical PSMA-TRT studies are able to test and compare
a wide range of methods in a high throughput manner in order to ultimately improving PSMA-TRT
therapeutic effectiveness while simultaneously decreasing the uptake in the healthy PSMA-expressing
kidneys and salivary glands. Improving already existing PSMA-targeting tracers, creating bi-ligands,
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experimenting with various radionuclides, enhancing therapeutic effects by using radio-sensitizers, and
looking for compounds that selectively block the healthy PMSA-expressing organs from PSMA-TRT are
major focus points in PSMA preclinical research. The preclinical studies discussed here and ongoing
preclinical research will inevitably determine the future of PSMA-TRT in the clinic.
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